2-ethoxy-1-nitronaphthalene | 117-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-ethoxy-1-nitronaphthalene
• 英文别名: ethyl-(1-nitro-[2]naphthyl)-ether；Aethyl-(1-nitro-[2]naphthyl)-aether；1-Nitro-2-aethoxy-naphthalin；1-Nitro-2-ethoxy-naphthalin
• CAS: 117-17-9
• 化学式: C₁₂H₁₁NO₃
• 分子量: 217.224
• InChiKey: OLTPLWKHHZTLJB-UHFFFAOYSA-N

物化性质

• 熔点：
  104-105 °C
• 沸点：
  368.3±17.0 °C(Predicted)
• 密度：
  1.234±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethoxy-1-nitronaphthalene 在 乙醇 、 氨 、 硝酸 作用下， 生成 2-amino-1,8-dinitronaphthalene
  参考文献：
  名称：

  Gaess, Journal fur praktische Chemie (Leipzig 1954), 1891, vol. <2> 43, p. 22

  摘要：

  DOI：
• 作为产物：
  描述：

  乙位萘乙醚 在 dinitrogen tetraoxide 、 溶剂黄146 作用下， 生成 2-ethoxy-1-nitronaphthalene
  参考文献：
  名称：

  Ryan; Keane, Scientific Proceedings of the Royal Dublin Society, 1924, vol. 17, p. 287,294

  摘要：

  DOI：

文献信息

• Synthesis and Muscarinic Activity of a Series of Quinolines and Naphthalenes with a 1-Azabicyclo(3.3.0)octane Moiety.
  作者：Tomoo SUZUKI、Toshinao USUI、Mitsuru OKA、Tsunemasa SUZUKI、Tadashi KATAOKA

  DOI：10.1248/cpb.46.1265

  日期：——

  synthesized a series of quinoline derivatives having a characteristic 1-azabicyclo[3.3.0]octane amine ring, and performed pharmacological evaluation of them. Acetylcholine esterase inhibitory activities of these derivatives were unexpectedly weak. Tests for central nervous muscarinic cholinergic receptor binding affinity indicated that these compounds had higher affinities to muscarinic M1 receptors than to

  为了发现对阿尔茨海默氏病有效的药物，我们合成了一系列具有特征性的1-氮杂双环[3.3.0]辛烷胺环的喹啉衍生物，并对其进行了药理学评价。这些衍生物的乙酰胆碱酯酶抑制活性出乎意料地弱。对中枢神经毒蕈碱胆碱能受体结合亲和力的测试表明，这些化合物对毒蕈碱M1受体的亲和力高于对M2受体的亲和力。还合成了一系列被1-氮杂双环[3.3.0]辛烷环取代的萘衍生物，并确定了毒蕈碱M1和M2受体的结合亲和力。这些化合物对M1受体的亲和力比喹啉衍生物和1- [N-（1-氮杂双环[3.3]。0]辛基-5-基）甲基-N-甲基氨基] -4-硝基萘具有最高的亲和力和选择性。使用东avoid碱诱导的小鼠的被动回避测试评估了该化合物改善认知功能的能力。
• Nootropic agents, compositions of, and method of use thereof
  申请人：Sanawa Kagaku Kenkyusho Company, Ltd.

  公开号：US05434165A1

  公开（公告）日：1995-07-18

  An aromatic amino-substituted compound represented by formula: ##STR1## wherein A represents CH, N, or N.fwdarw.O; R.sub.1 represents a nitro group or an amino group; R.sub.2 represents a hydrogen atom, a lower alkyl group, or an acyl group; and R.sub.3 represents a group: ##STR2## wherein m represents 0 or 1; n represents an integer of from 0 to 3; R.sub.4 and R.sub.5 each represents a hydrogen atom or a lower alkyl group; R.sub.6 and R.sub.7 each represents a hydrogen atom or a straight chain or branched lower alkyl group; R.sub.4 and R.sub.6 may be joined together to form an alkylene chain forming a heterocyclic ring; R.sub.5 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring and R.sub.6 and R.sub.7 may be joined together to form an alkylene chain forming a heterocyclic ring, or a pharmaceutically acceptable salt thereof, a process for producing the same, and a method for preventing or treating brain disfunction such as senile dementia or Alzheimer's disease by administering a nootropic agent containing the same as an active ingredient are disclosed.

  一种芳香族氨基取代化合物，其化学式表示为：##STR1## 其中A代表CH、N或N.fwdarw.O；R.sub.1代表硝基基团或氨基团；R.sub.2代表氢原子、较低的烷基基团或酰基团；R.sub.3代表一个基团：##STR2## 其中m表示0或1；n表示0到3的整数；R.sub.4和R.sub.5分别代表氢原子或较低的烷基基团；R.sub.6和R.sub.7分别代表氢原子或直链或支链较低的烷基基团；R.sub.4和R.sub.6可以结合在一起形成形成杂环环的烷基链；R.sub.5和R.sub.7可以结合在一起形成形成杂环环的烷基链，R.sub.6和R.sub.7可以结合在一起形成形成杂环环的烷基链，或其药学上可接受的盐，公开了一种制备该化合物的方法，以及通过给予含有该化合物作为活性成分的智力药剂来预防或治疗脑功能障碍，如老年性痴呆症或阿尔茨海默病的方法。
• Preparation of fluoronitronaphthalenes via a modified Schiemann reaction
  作者：Earl Brill

  DOI：10.1039/j39660000748

  日期：——

  1-Fluoro-2-nitro-, and 2-fluoro-1-nitro-naphthalene were prepared in 10–15% yields by the diazotisation of the corresponding nitroamine fluoborate salts in tetrahydrofuran, followed by decomposition of the diazonium fluoborate salts. This is the first reported synthesis of 1-fluoro-2-nitronaphthalene.

  通过将相应的硝基胺氟硼酸盐在四氢呋喃中重氮化，然后分解氟硼酸重氮盐，可以10-15％的收率制备1-氟-2-硝基萘和2-氟-1-硝基萘。这是首次报道的1-氟-2-硝基萘的合成。
• Laryngeal Stenosis after Supracricoid Partial Laryngectomy
  作者：Eduardo M. Diaz、Dominique Garcia、Laurent Laccourreye、Daniel Brasnu、David Veivers、Ollivier Laccourreye

  DOI：10.1177/000348940010901115

  日期：2000.11

  The purpose of this study was to review the incidence, risks, management, and outcomes of nontumoral laryngeal stenosis after supracricoid partial laryngectomy (SCPL) in a case series of 376 consecutive SCPLs performed at 1 institution from 1975 to 1995 with a minimum of 3 years of follow-up. Post-SCPL nontumoral symptomatic laryngeal stenosis was defined as an inability to decannulate patients before the 60th postoperative day (group 1) or the development of dyspnea (in patients without local recurrence) after an initial period of prolonged, successful decannulation (group 2). Of 376 SCPLs performed, nontumoral symptomatic laryngeal stenosis developed in 14 (3.7%). There were 7 patients (1.85%) in group 1 and 7 patients (1.85%) in group 2. In univariate analysis, none of the following variables appeared to be statistically related to the risk of immediate stenosis (group 1): age, gender, comorbidity, diabetes mellitus, symptomatic gastroesophageal reflux, arteritis, preoperative radiotherapy, arytenoid cartilage disarticulation, type of reconstruction performed, and postoperative radiotherapy. A delayed laryngeal stenosis (group 2) was statistically more likely to occur if the reconstruction performed at the time of SCPL was a cricohyoidopexy (p = .01). Successful management of the laryngeal stenosis without permanent tracheostomy was achieved in 5 group 1 patients and 3 group 2 patients. We believe that stenosis in group 1 patients arose through technical error, whereas group 2 patients seemed to suffer from problems of healing, mainly cicatricial narrowing of the airway at the site of the cricohyoidal impaction, or pexis. As a result, whereas laryngeal stenosis in group 1 patients was usually more easily correctable through dilation, laser incision, or resection of redundant tissue or revision of the impaction, laryngeal stenosis in group 2 patients presented a more difficult and frustrating complication. The management and outcomes of these patients are presented.

  这项研究的目的是回顾1975年至1995年在一家机构进行的连续376例超环喉部分喉切除术（SCPL）后非肿瘤性喉狭窄的发生率、风险、管理和结果，其中至少有3年的随访时间。术后SCPL非肿瘤性症状性喉狭窄被定义为术后60天前无法拔管的患者（第1组）或在初始较长时间的成功拔管后出现呼吸困难（无局部复发患者）（第2组）。在进行的376例SCPL中，非肿瘤性症状性喉狭窄发生在14例（3.7%）患者中。第1组有7例患者（1.85%），第2组有7例患者（1.85%）。在单变量分析中，以下变量似乎与即时狭窄风险（第1组）无统计学相关性：年龄、性别、合并疾病、糖尿病、症状性胃食管反流、动脉炎、术前放疗、杓软骨脱位、重建类型以及术后放疗。如果SCPL时进行的重建是环喉固定术（p = .01），则延迟性喉狭窄（第2组）更有可能发生。在第1组患者中，成功管理喉狭窄并避免永久气管切开术的有5例患者，第2组患者有3例。我们认为第1组患者的狭窄是由技术错误引起的，而第2组患者似乎遭受愈合问题，主要是环喉固定术的部位出现瘢痕性气道狭窄。因此，虽然第1组患者的喉狭窄通常更容易通过扩张、激光切开、冗余组织切除或修正固定来纠正，但第2组患者的喉狭窄则是一种更为困难和令人沮丧的并发症。这些患者的管理和结果被提出。
• Francis, Chemische Berichte, 1906, vol. 39, p. 3801
  作者：Francis

  DOI：——

  日期：——